Table 2.

Univariate and multivariate logistic regression analysis for overall response rate (n = 152)

Variable	Univariate analysis				Multivariate analysis
	ORR, %	OR	95% CI	P value	OR	95% CI	P value
Experimental therapy
IO monotherapy	11.9	Ref
IO combination	11.8	0.99	0.37–2.86	.995
Age
<65	10.4	Ref
≥65	15.2	1.55	0.54–4.24	.399
Sex
Female	8.9	Ref
Male	16.1	1.97	0.73–5.48	.180
PS ECOG
0	17.1	Ref
≥1	5.6	0.29	0.08–0.84	.035	0.28	0.09–0.94	.039
Visceral metastases
No	14.6	Ref
Yes	10.8	0.71	0.25–2.16	.519
Metastatic sites
≤2	17.0	Ref
>2	4.7	0.24	0.05–0.77	.029	0.28	0.08–1.07	.062
Prior lines of therapy
≤2	17.4	Ref
>2	3.3	0.16	0.03–0.61	.019	0.18	0.04–0.82	.027
LDH
< ULN	19.4	Ref
> ULN	11.3	0.53	0.17–1.49	.242
NLR
<6	13.6	Ref
≥6	3.7	0.24	0.01–1.28	.180
dNLR
<3	13.2	Ref
≥3	6.7	0.47	0.07–1.78	.331
PLR
<300	12.2	Ref
≥300	10.8	0.87	0.24–2.64	.823
LMR
<3	11.8	Ref
≥3	12.1	1.03	0.28–3.14	.955
Albumin
≤3.5	5.3	Ref
>3.5	12.8	2.64	0.492–48.96	0.360

Abbreviations: CI, confidence interval; dNLR, derived neutrophil‐to‐lymphocyte ratio; IO, immunotherapy; LMR, lymphocyte‐to‐monocyte ratio; OR, odds ratio; ORR, overall response rate; NLR, neutrophil‐to‐lymphocyte ratio; PLR, platelet‐to‐lymphocyte ratio; PS ECOG, performance status according to Eastern Cooperative Oncology Group; ULN, upper limit of normal.